Risk-Based Selection of Environmental Classifications for Biopharmaceutical Operations

References

1. 1.↵
   European Commission, EudraLex—The Rules Governing Medicinal Products in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 2 Manufacture of Biological Medicinal Products for Human Use. European Commission: Brussels, 2018.

   Google Scholar
2. 2.↵
   1. Blake J.,
   2. Estape D.,
   3. Green K.,
   4. Iyer K. R.,
   5. Johnson J.,
   6. Mcduff P.,
   7. Pelletier M.,
   8. Powell A.,
   9. Probst S.,
   10. Smock P.,
   11. Payne R.,
   12. Corbidge T.

   BPOG Response to Annex 2 PDA J. Pharm. Sci. Technol. 2016, 70 (3), 300–311.

   OpenUrlFREE Full TextGoogle Scholar
3. 3.↵
   1. Probst S.,
   2. Pancorbo J.,
   3. Pelletier M.,
   4. Afanado N. L.,
   5. Iyer K. R.,
   6. Johnson J. C.,
   7. Corbidge T.

   Data-Driven Equipment and Facility Design Case Study: Functional Closure of a Hybrid Connection System, 2018. BioPhorum Web site. https://www.biophorum.com/download/data-driven-equipment-and-facility-design-case-study/ (accessed June 10, 2021).

   Google Scholar
4. 4.↵
   1. Pelletier M.

   Death to Cleanrooms in Biopharmaceutical Manufacturing, PAP-Q1-18-CL-006, 2018. Pharma’s Almanac Web site. https://www.pharmasalmanac.com/articles/death-to-cleanrooms-in-biopharmaceutical-manufacturing (accessed June 10, 2021).

   Google Scholar
5. 5.↵
   International Society for Pharmaceutical Engineering, ISPE Baseline Guide Volume 6: Biopharmaceutical Manufacturing Facilities. ISPE: Tampa, FL, 2013.

   Google Scholar
6. 6.↵
   1. Estapé D.,
   2. Walker A. L.,
   3. Orichowskyj S. T.,
   4. Vega H.,
   5. Pratt D. J.

   Proof of Closure: Life Cycle of Closed Systems. Pharm. Eng. 2017, 37 (5), 51–59.

   OpenUrlGoogle Scholar
7. 7.↵
   1. Whyte W.,
   2. Eaton T.

   A Cleanroom Contamination Control System. Eur. J. Parenter. Pharm. Sci. 2002, 7 (2), 55–61.

   OpenUrlGoogle Scholar
8. 8.↵
   1. Whyte W.,
   2. Eaton T.

   Microbiological Contamination Models for Use in Risk Assessment during Pharmaceutical Production. Eur. J. Parenter. Pharm. Sci. 2004, 9 (1), 11–15.

   OpenUrlGoogle Scholar
9. 9.↵
   1. Whyte W.,
   2. Eaton T.

   Microbial Risk Assessment in Pharmaceutical Cleanrooms. Eur. J. Parenter. Pharm. Sci. 2004, 9 (1), 16–23.

   OpenUrlGoogle Scholar
10. 10.↵
    1. Bain D.,
    2. Hardy D.,
    3. Bell B. L.,
    4. Forng R. Y.,
    5. Knight M.,
    6. Bawa A.,
    7. Ramsey S.,
    8. Arbesser-Rastburg C.,
    9. Paul M.,
    10. Ton C.,
    11. Leira F.,
    12. Roman C.,
    13. McFarland K.,
    14. Phillips D.,
    15. Stuckey J.,
    16. Bauer C.,
    17. Calvo A. J.

    Microbial Monitoring for Biological Drug Substance Manufacturing: An Industry Perspective. PDA J. Pharm. Sci. Technol. 2015, 69 (3), 451–456.

    OpenUrlFREE Full TextGoogle Scholar
11. 11.↵
    International Conference for Harmonisation, Quality Guideline Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients. ICH: Geneva, 2000.

    Google Scholar
12. 12.↵
    European Commission, EudraLex—The Rules Governing Medicinal Products in the European Union, Volume 4: Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products. European Commission: Brussels, 2008.

    Google Scholar
13. 13.↵
    Pharmaceutical Inspection Convention/Cooperation Scheme, Guide to Good Manufacturing Practice for Medicinal Products—Annex II: Manufacture of Biological Medicinal Substances and Products for Human Use. PIC/S: Geneva, 2017.

    Google Scholar
14. 14.↵
    1. Bourdichon F.,
    2. Ben Cheikh M. H.

    New Food [Online] 2010, (5). https://www.newfoodmagazine.com/article/3102/predictive-modelling-of-microbial-behaviour-in-foods-an-industrial-perspective-and-applications/ (accessed June 10, 2021).

    Google Scholar
15. 15.↵
    1. Monod J.

    The Growth of Bacterial Cultures. Annu. Rev. Microbiol. 1949, 3 (1), 371–394.

    OpenUrlCrossRefWeb of ScienceGoogle Scholar